Literature DB >> 27125514

The management of osteoporosis in children.

L M Ward1,2, V N Konji3, J Ma3,4.   

Abstract

This article reviews the manifestations and risk factors associated with osteoporosis in childhood, the definition of osteoporosis and recommendations for monitoring and prevention. As well, this article discusses when a child should be considered a candidate for osteoporosis therapy, which agents should be prescribed, duration of therapy and side effects. There has been significant progress in our understanding of risk factors and the natural history of osteoporosis in children over the past number of years. This knowledge has fostered the development of logical approaches to the diagnosis, monitoring, and optimal timing of osteoporosis intervention in this setting. Current management strategies are predicated upon monitoring at-risk children to identify and then treat earlier rather than later signs of osteoporosis in those with limited potential for spontaneous recovery. On the other hand, trials addressing the prevention of the first-ever fracture are still needed for children who have both a high likelihood of developing fractures and less potential for recovery. This review focuses on the evidence that shapes the current approach to diagnosis, monitoring, and treatment of osteoporosis in childhood, with emphasis on the key pediatric-specific biological principles that are pivotal to the overall approach and on the main questions with which clinicians struggle on a daily basis. The scope of this article is to review the manifestations of and risk factors for primary and secondary osteoporosis in children, to discuss the definition of pediatric osteoporosis, and to summarize recommendations for monitoring and prevention of bone fragility. As well, this article reviews when a child is a candidate for osteoporosis therapy, which agents and doses should be prescribed, the duration of therapy, how the response to therapy is adjudicated, and the short- and long-term side effects. With this information, the bone health clinician will be poised to diagnose osteoporosis in children and to identify when children need osteoporosis therapy and the clinical outcomes that gauge efficacy and safety of treatment.

Entities:  

Keywords:  Bisphosphonates; Bone density; Bone fragility; Denosumab; Diagnosis; Monitoring; Osteoporosis; Treatment; Vertebral fractures

Mesh:

Substances:

Year:  2016        PMID: 27125514     DOI: 10.1007/s00198-016-3515-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  192 in total

1.  Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.

Authors:  Edip Unal; Ayhan Abaci; Ece Bober; Atilla Büyükgebiz
Journal:  J Pediatr Endocrinol Metab       Date:  2006-04       Impact factor: 1.634

2.  Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.

Authors:  Daniela Marinovic; Sophie Dorgeret; Brigitte Lescoeur; Corinne Alberti; Michèle Noel; Paul Czernichow; Guy Sebag; Etienne Vilmer; Juliane Léger
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

3.  Whole-exome sequencing reveals a heterozygous LRP5 mutation in a 6-year-old boy with vertebral compression fractures and low trabecular bone density.

Authors:  Somayyeh Fahiminiya; Jacek Majewski; Peter Roughley; Paul Roschger; Klaus Klaushofer; Frank Rauch
Journal:  Bone       Date:  2013-07-23       Impact factor: 4.398

4.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

5.  Improvements in Bone Density and Structure during Anti-TNF-α Therapy in Pediatric Crohn's Disease.

Authors:  Lindsay M Griffin; Meena Thayu; Robert N Baldassano; Mark D DeBoer; Babette S Zemel; Michelle R Denburg; Lee A Denson; Justine Shults; Rita Herskovitz; Jin Long; Mary B Leonard
Journal:  J Clin Endocrinol Metab       Date:  2015-04-28       Impact factor: 5.958

6.  Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I.

Authors:  Frank Rauch; Liljana Lalic; Peter Roughley; Francis H Glorieux
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

7.  Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis.

Authors:  Min Jeong Kim; Soo-Nyung Kim; In-Sik Lee; Sochung Chung; Joonchul Lee; YouNa Yang; Inho Lee; Seong-Eun Koh
Journal:  J Pediatr Endocrinol Metab       Date:  2015-11-01       Impact factor: 1.634

8.  Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.

Authors:  Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth A Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

9.  Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?

Authors:  J J Brown; L Ramalingam; M R Zacharin
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-21       Impact factor: 3.478

10.  Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes.

Authors:  Pontipa Engkakul; Pat Mahachoklertwattana; Suphaneewan Jaovisidha; Ampaiwan Chuansumrit; Preamrudee Poomthavorn; Niyata Chitrapazt; Suporn Chuncharunee
Journal:  J Pediatr Hematol Oncol       Date:  2013-04       Impact factor: 1.289

View more
  30 in total

Review 1.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

Review 2.  Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.

Authors:  Monica Grover; Laura K Bachrach
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 3.  Dual-energy X-ray absorptiometry bone densitometry in pediatrics: a practical review and update.

Authors:  Hedieh Khalatbari; Larry A Binkovitz; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2020-08-28

Review 4.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

5.  The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.

Authors:  J Ma; H J McMillan; G Karagüzel; C Goodin; J Wasson; M A Matzinger; P DesClouds; D Cram; M Page; V N Konji; B Lentle; L M Ward
Journal:  Osteoporos Int       Date:  2016-10-24       Impact factor: 4.507

6.  Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta.

Authors:  G Bardai; L M Ward; P Trejo; P Moffatt; F H Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2017-04-04       Impact factor: 4.507

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 8.  Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; David R Weber
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

9.  Systematic review of the effects of bisphosphonates on bone density and fracture incidence in childhood acute lymphoblastic leukaemia.

Authors:  A M Harris; A R Lee; S C Wong
Journal:  Osteoporos Int       Date:  2019-08-03       Impact factor: 4.507

Review 10.  Anabolic Therapy for the Treatment of Osteoporosis in Childhood.

Authors:  Leanne M Ward; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.